Epidural Stimulation After Spinal Cord Injury

Spinal Cord Injuries Clinical Trial

— ESL-SCI  

Official title:

Epidural Stimulation for Locomotion After Spinal Cord Injury

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04105296
• Other study ID #: 2501
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 2020
• Est. completion date: December 30, 2021

Study information

• Verified date: October 2019
• Source: McGuire Research Institute
• Contact: Ashraf S Gorgey, PhD
• Phone: 8046755000
• Email: ashraf.gorgey[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the current study is to determine the effects of applying epidural stimulation (ES) on motor control recovery in Veterans with SCI. The intervention will be accompanied with the use of a powered exoskeleton (EKSO®) for 6 months to facilitate standing and to produce step-like movement in persons with chronic motor complete (AIS A or B) SCI and level of injury below C5 . Walking speed, distance, muscle activation pattern as measured by surface EMG and walking parameters including stand-up time, walking time, distance will be considered primary outcome variables. Cardiovascular performance, as measured by resting blood pressure and heart rate, peak oxygen consumption during walking, energy expenditure, whole and regional body composition assessments will also be measured. The effects of training (ES+EKSO) on , and speed of walking will also be evaluated.

Description:

Five veterans with chronic motor complete SCI (AIS A or B) will be recruited to participate in the current trial. The primary objective is to determine how implantation of an epidural stimulator can help to control movement in the leg muscles to stand and perform stepping. Participants will be trained using a robotic suit and parallel bars. The procedure of using epidural stimulation with the robotic suit is experimental. The participant will be scheduled to perform temporary implantation followed by permanent implantation. Seven days later, two 8-electrode arrays of Vectris lead will be implanted in an operating room. The research team will be responsible for helping the participants to trigger the paralyzed muscles from supine and sitting using for 5 days per week. Participants would be required to come for study visits twice daily for 2 hours per day. Each visit will last approximately 1 hour in the morning and 1 hour in the evening. During these visits, participants will practice walking with a robotic suit for 30-60 minutes followed by overground walking between parallel bars, or with a walker or crutches.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 5
• Est. completion date: December 30, 2021
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. A written clearance by the medical doctor to ensure that the participant is safely able to engage in the program.

2. Participants who require assistance with activities of daily living, must have a caregiver or companion with them throughout their participation in the study.

3. Participants will have to be 2 years post-injury with any level of injury below C5 and using wheelchair as the primary mode of mobility. The study is primarily exploratory, and all participants will be between 18-70 years old with SCI.

4. Hip width (distance between two greater trochanters), upper leg length (greater trochanter to the lateral aspect of joint line of the knee joint) and lower leg length (lateral aspect of joint line of the knee joint to the bottom of the foot) that can fit the robotic suit.

Exclusion Criteria:

1. Unhealed fracture in either lower or upper extremities

2. Severe scoliosis, hip knee ROM or flexion knee contractures preventing positioning in an exoskeleton or plantarflexion deformity greater than 20 degrees.

3. High resting blood pressure greater than 140/80 mmHg and or sudden hypotension upon standing as characterized by drop in blood pressure by 20 mmHg especially in persons with tetraplegia.

4. Other medical conditions including cardiovascular disease, uncontrolled type II DM, uncontrolled hypertension, and those on insulin, pressures sores stage 3 or greater, or symptomatic urinary tract infection.

5. Unable to fit in the device for any reason.

6. Taking anti-coagulants or anti-platelet agents, including aspirin if unable to be off this medication for medical reasons.

7. Implanted pacemakers and/or implanted defibrillator devices.

8. Any condition that, in the judgment of the principal investigator or medical provider, precludes safe participation in the study and/or increases the risk of infection.

9. Dual Energy X-ray Absorptiometry (DXA) T-Score less than -2.5. Scans done will include total body, dual hips and knees.

10. Functional upper and lower extremity range of motion (ROM), strength, spasticity and skin integrity will also have assessed prior to enrollment in the program. The Modified Ashworth Scale will be used to ensure safety of the participants prior to engagement in the rehabilitation program. Participants with severe spasticity or limited ROM will be excluded in the trial. This will be done based on the manufacture's recommendation.

11. Other exclusion criteria may include the followings

• subjects with uncontrolled autonomic dysreflexia

• subjects with concurrent severe neurological injuries other than SCI: MS, CP, TBI, stroke;

• subjects with unresolved deep vein thrombosis (DVT);

• subjects with prosthetic lower limbs;

• subjects with psychiatric or cognitive impairments which will interfere with proper operation of both the spinal cord stimulator as well as the exoskeleton;

• subjects with an unhealed spinal fracture or unstable spine; and

• subjects with known cardiac pathology which precludes safe participation

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Wounds and Injuries

Intervention

Device:
• EKSO+ES
6 months of exoskeleton training with epidural stimulation.

Locations

Country	Name	City	State
United States	Hunter Holmes McGuire VA Medical Center	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
McGuire Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Six minute-walk and 10-meter walk distance Tests	Walking distance and speed will also be determined	6 months
Primary	Surface electromyography of 6 different muscle groups	The EMG activity from 6 major leg muscles will be measured during locomotion	6 months
Secondary	Systolic and Diastolic Blood Pressure	During sitting, standing and walking	6 months
Secondary	Oxygen uptake using Portable Indirect Calorimetry	During sitting, standing and walking	6 months
Secondary	Body composition assessment of fat mass and fat-free mass using dual energy x-ray absorptiometry (DXA)	Before and after training	6 months